Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OGB 21502

X
Drug Profile

OGB 21502

Alternative Names: OGB-21502

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onegene Biotechnology
  • Class Anti-inflammatories; Hepatoprotectants; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor 21 modulators; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 10 Nov 2023 Pharmacodynamics data from a Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 07 Sep 2023 Onegene Biotechnology plans to file an IND application in 2024
  • 21 Jun 2023 Pharmacodynamics data from preclinical trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top